New York State Common Retirement Fund Invests $4.02 Million in Heartflow, Inc. $HTFL

New York State Common Retirement Fund acquired a new stake in Heartflow, Inc. (NASDAQ:HTFL) during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 119,289 shares of the company’s stock, valued at approximately $4,015,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Y Intercept Hong Kong Ltd bought a new position in shares of Heartflow in the 3rd quarter valued at $234,000. Baillie Gifford & Co. acquired a new stake in Heartflow in the third quarter valued at about $101,182,000. TrueMark Investments LLC bought a new position in Heartflow in the third quarter valued at about $918,000. Emerald Mutual Fund Advisers Trust acquired a new position in Heartflow during the third quarter worth about $4,418,000. Finally, TFC Financial Management Inc. bought a new position in shares of Heartflow in the third quarter worth about $40,000.

Analyst Ratings Changes

Several equities research analysts recently issued reports on HTFL shares. Canaccord Genuity Group lifted their price target on shares of Heartflow from $39.00 to $40.00 and gave the company a “buy” rating in a report on Thursday, November 13th. Wells Fargo & Company began coverage on shares of Heartflow in a report on Wednesday, January 28th. They set an “overweight” rating and a $38.00 price target for the company. Stifel Nicolaus raised their price objective on Heartflow from $35.00 to $40.00 and gave the company a “buy” rating in a report on Thursday, November 13th. JPMorgan Chase & Co. upped their target price on Heartflow from $36.00 to $40.00 and gave the stock an “overweight” rating in a report on Thursday, November 13th. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Heartflow in a research report on Monday, December 29th. Five research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $38.50.

Heartflow Trading Up 6.7%

Shares of Heartflow stock opened at $27.74 on Friday. The company has a market capitalization of $2.36 billion and a PE ratio of -15.33. Heartflow, Inc. has a twelve month low of $25.38 and a twelve month high of $41.22. The business has a fifty day simple moving average of $30.33.

Insider Activity

In related news, Director Jeffrey C. Lightcap acquired 40,000 shares of the stock in a transaction dated Tuesday, December 16th. The stock was bought at an average cost of $26.34 per share, for a total transaction of $1,053,600.00. Following the completion of the transaction, the director directly owned 40,000 shares of the company’s stock, valued at $1,053,600. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Bain Capital Life Sciences Inv sold 2,000,000 shares of Heartflow stock in a transaction that occurred on Wednesday, February 4th. The stock was sold at an average price of $28.05, for a total value of $56,100,000.00. Following the completion of the transaction, the insider directly owned 10,448,158 shares in the company, valued at approximately $293,070,831.90. This represents a 16.07% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure.

About Heartflow

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.